0001145549-21-015585.txt : 20210311 0001145549-21-015585.hdr.sgml : 20210311 20210311125842 ACCESSION NUMBER: 0001145549-21-015585 CONFORMED SUBMISSION TYPE: N-CEN PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20201231 FILED AS OF DATE: 20210311 DATE AS OF CHANGE: 20210311 EFFECTIVENESS DATE: 20210311 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Gabelli Go Anywhere Trust CENTRAL INDEX KEY: 0001635193 IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: N-CEN SEC ACT: 1940 Act SEC FILE NUMBER: 811-23035 FILM NUMBER: 21732627 BUSINESS ADDRESS: STREET 1: ONE CORPORATE CENTER CITY: RYE STATE: NY ZIP: 10580-1022 BUSINESS PHONE: 914-921-5100 MAIL ADDRESS: STREET 1: ONE CORPORATE CENTER CITY: RYE STATE: NY ZIP: 10580-1022 N-CEN 1 primary_doc.xml X0303 N-CEN LIVE 0001635193 XXXXXXXX false false false N-2 Gabelli Go Anywhere Trust 811-23035 0001635193 5493002YIVP4S847QX53 One Corporate Center Rye 10580-1422 US-NY US 1-800-422-3554 The Bank of New York Mellon 240 Greenwich Street New York 10286 1-212-495-1784 Custody BNY Mellon Investment Servicing (US) Inc. 301 Bellevue Parkway Wilmington 19809 1-302-791-1700 Accounting Gabelli Funds, LLC One Corporate Center Rye 10580-1422 914-921-5100 Accounting Computershare Trust Company, N.A. 462 South 4th Street Louisville 40202 502-301-6000 Transfer Agent N N N-2 Y Anthony S. Colavita N/A N Michael J. Melarkey N/A N Kuni Nakamura N/A N Mario J. Gabelli 000216136 Y Frank J. Fahrenkopf, Jr. N/A N Richard J. Walz 001392836 One Corporate Center Rye 10580 XXXXXX N N N N N N N Ernst & Young LLP 42 N/A N N N N N Gabelli Go Anywhere Trust 5493002YIVP4S847QX53 N 0 0 0 N/A Y N Y N N/A N/A N/A Rule 17e-1 (17 CFR 270.17e-1) N N N N Gabelli Funds, LLC 801-37706 000104949 549300JDTNRQK8NMTG03 N Computershare Trust Company, N.A. 85-11340 2549001YYB62BVMSAO13 N N N Intercontinental Exchange, Inc. 5493000F4ZO33MV32P92 N N The Bank of New York Mellon HPFHU0OQ28E4N0NFVK49 N N Bank - section 17(f)(1) (15 U.S.C. 80a-17(f)(1)) N Computershare Trust Company, N.A. 2549001YYB62BVMSAO13 N N N BNY Mellon Investment Servicing (US) Inc. 549300CFZQLI9QMJ1Z03 N Y Gabelli Funds, LLC 549300JDTNRQK8NMTG03 Y N N G.Research, LLC 008-21373 000007353 N/A 16698.000000000000 G.distributors, LLC 008-68697 000155071 N/A 0.000000000000 SIDOTI & COMPANY, LLC 008-52141 000102860 254900FHBEGNA4NAO961 3000.000000000000 STONEX FINANCIAL INC. 008-51269 000045993 549300LNKU6K5TJCRG93 730.000000000000 Stifel, Nicolaus & Company, Incorporated 008-01447 000000793 5WUVMA08EYG4KEUPW589 500.000000000000 WELLS FARGO CLEARING SERVICES, LLC 008-37180 000019616 88KRVSOEKUGQZJ3DKW55 2064.000000000000 G.RESEARCH, LLC 008-21373 000007353 N/A 16698.000000000000 Cowen and Company, LLC 008-22522 000007616 549300WR155U7DVMIW58 1713.000000000000 Needham & Company, LLC 008-33772 000016360 254900J2GFQ4J4NK1J89 1435.000000000000 MORGAN STANLEY & CO. LLC 008-15869 000008209 9R7GPTSO7KV3UQJZQ078 6249.000000000000 CANTOR FITZGERALD & CO. 008-00201 000000134 5493004J7H4GCPG6OB62 538.000000000000 UBS Securities LLC 008-22651 000007654 T6FIZBDPKLYJKFCRVK44 3476.000000000000 38113.000000000000 Inspire Brands N/A N/A N/A 1065000.000000000000 JOHNSON & JOHNSON N/A N/A 549300G0CFPGEF6X2043 1312500.000000000000 Gilead Sciences, Inc. N/A N/A 549300WTZWR07K8MNV44 1056000.000000000000 Aimmune Therapeutics, Inc. N/A N/A 549300WDF7T2EVBC1877 690000.000000000000 THE HOME DEPOT, INC. N/A N/A QEKMOTMBBKA8I816DO57 1120000.000000000000 Daiwa Capital Markets America, Inc. 008-12242 000001576 M67H5PRC0NQKM73ZAS82 19745598.000000000000 RBC CAPITAL MARKETS LLC 008-45411 000031194 549300LCO2FLSSVFFR64 7957477.000000000000 NOMURA SECURITIES INTERNATIONAL, INC. 008-15255 000004297 OXTKY6Q8X53C9ILVV871 13591373.000000000000 BMO CAPITAL MARKETS CORP. 008-34344 000016686 RUC0QBLBRPRCU4W1NE59 3217864.000000000000 BARCLAYS CAPITAL, INC. 008-41342 000019714 AC28XWWI3WIBK2824319 25407458.000000000000 78737309.000000000000 Y 33764611.000000000000 0.000000000000 Common stock C000000000 Preferred stock Series A Cumulative Preferred Shares N N Common stock Preferred stock N N N 1.170000000000 3.080000000000 12.00 14.180000000000 true INTERNAL CONTROL RPT 2 internalcontrolrpt_ggo.htm

Report of Independent Registered Public Accounting Firm

To the Shareholders and

Board of Trustees of The Gabelli Go Anywhere Trust

In planning and performing our audit of the financial statements of The Gabelli Go Anywhere Trust (the “Fund”) as of and for the year ended December 31, 2020, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), we considered the Fund’s internal control over financial reporting, including controls over safeguarding securities, as a basis for designing our auditing procedures for the purpose of expressing our opinion on the financial statements and to comply with the requirements of Form N-CEN, but not for the purpose of expressing an opinion on the effectiveness of the Fund’s internal control over financial reporting. Accordingly, we express no such opinion.

The management of the Fund is responsible for establishing and maintaining effective internal control over financial reporting. In fulfilling this responsibility, estimates and judgments by management are required to assess the expected benefits and related costs of controls. A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and trustees of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of a company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

A deficiency in internal control over financial reporting exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent or detect misstatements on a timely basis. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Fund’s annual or interim financial statements will not be prevented or detected on a timely basis.

Our consideration of the Fund’s internal control over financial reporting was for the limited purpose described in the first paragraph and would not necessarily disclose all deficiencies in internal control that might be material weaknesses under standards established by the PCAOB. However, we noted no deficiencies in the Fund’s internal control over financial reporting and its operation, including controls over safeguarding securities, that we consider to be a material weakness as defined above as of December 31, 2020.

This report is intended solely for the information and use of management and the Board of Trustees of The Gabelli Go Anywhere Trust and the Securities and Exchange Commission and is not intended to be and should not be used by anyone other than these specified parties.

/s/ Ernst & Young LLP

Philadelphia, Pennsylvania

February 26, 2021